GDG.ASX RZI.ASX PWH.ASX BOT.ASX RMD.ASX

Strong Q1 Performance for Generation Development Group

Generation Development Group (ASX:GDG) delivered a strong performance in the March quarter, with growth across its Evidentia Group, Generation Life, and Lonsec Research and Ratings businesses. The company remains well-positioned as the market leader in the managed accounts sector.

Evidentia Group's funds under management (FUM) reached $26.8 billion, up 28% year-over-year, while Generation Life achieved record quarterly inflows of $239 million, up 55% year-over-year. Lonsec Research and Ratings also delivered strong revenue growth.

The integration of Lonsec Investment Solutions, Implemented Portfolios, and Evidentia is progressing to plan, with key milestones being met. Generation Development Group is now the market leader across all segments of the managed accounts sector, well-positioned to continue its growth trajectory.

Raiz Invest Delivers Solid Q3 FY25 Growth

Raiz Invest (ASX:RZI) reported solid growth in Q3 FY25, with a 6.9% year-over-year increase in Active Customers to 324,968, a 5.9% year-over-year increase in ARPU to $75.94, and strong quarterly net inflows of $60 million, up 67.9% on the prior corresponding period.

The company also saw continued growth across all customer segments, with Plus Portfolios up 42.5% year-over-year, Super Customers up 24.1% year-over-year, and Kids Portfolios up 36.3% year-over-year. Total FUM increased 23.1% year-over-year to $1.65 billion.

Raiz launched the Raiz Jars feature, which has seen strong uptake with 15,814 active Jar accounts, and was awarded the 2025 Canstar Innovation Excellence Award for Raiz Plus Portfolios. The company remains committed to ongoing product innovation and is well-positioned to continue its growth trajectory.

PWR Founder Takes Medical Leave, Matthew Bryson Appointed Acting CEO

PWR Holdings Ltd (ASX: PWH) has announced that its Managing Director and Founder, Kees Weel, is taking temporary leave from his full-time role to seek treatment for an acute medical condition. During Kees Weel's absence, PWR's Executive Leadership Team will assume his day-to-day responsibilities, with Chief Technical and Commercial Officer, Matthew Bryson, appointed by the Board to the role of Acting CEO.

Kees Weel has stated that while he will remain active in PWR's overall direction, his priority is concentrating on his recovery. The Board has expressed its support for Kees Weel's decision and has wished him all the best for his recovery, looking forward to welcoming him back when he is ready.

Botanix Pharmaceuticals Reports Successful Sofdra Launch

Botanix Pharmaceuticals has reported a successful commercial launch of its lead product Sofdra (sofpironium) topical gel, 12.45%, with strong growth in new patient arrivals, prescriber numbers, and refill rates.

New patient arrivals are now trending over 500 per week, at a run rate of more than 2,000 per month. Individual prescriber numbers are exceeding 400 per week, and more than 1,500 prescribers have written Sofdra prescriptions since the sales force launched. Refills in March 2025 reached 100% of eligible patients.

Based on the early performance of Sofdra, Botanix Pharmaceuticals has secured commitments for a $40 million capital raise to accelerate sales, marketing, and support activities, as well as expand the sales force and infrastructure, widen the digital platform and marketing/conference activities, and invest in inventory and logistics.

Resmed Declares Quarterly Dividend, Reports Strong Q3 FY25 Results

Resmed Inc (NYSE: RMD, ASX: RMD) has announced a quarterly dividend of USD 0.053 per share, payable on June 12, 2025 to shareholders of record as of May 8, 2025. The dividend relates to the financial reporting period ended March 31, 2025.

In addition, Resmed reported strong financial results for the third quarter of fiscal year 2025. Revenue increased by 8% to $1.3 billion, up 9% on a constant currency basis, driven by increased demand for sleep devices, masks, and solid growth in the Residential Care Software business. Gross margin improved 140 basis points to 59.3%, and non-GAAP gross margin improved 140 basis points to 59.9%. Income from operations increased 14%, and non-GAAP income from operations was up 13%.

Resmed expects to deliver strong financial performance in fiscal year 2025, with revenue growth of 8-10% and non-GAAP earnings per share growth of 10-12% compared to the prior year.